Prevalence of anti-platelet factor 4/polyanionic antibodies after COVID-19 vaccination with ChAdOx1 nCoV-19 and CoronaVac in Thais

CONCLUSION: We found a low prevalence of anti-PF4 antibodies in Thais after vaccination with ChAdOx1 nCoV-19 and CoronaVac. None of the antibodies were functional and lacked an association with VITT.PMID:34667921 | PMC:PMC8505225 | DOI:10.1002/rth2.12600
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Source Type: research

Related Links:

Abdellatif The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), also known as COVID-19, is currently developing into a rapidly disseminating and an overwhelming worldwide pandemic. In severe COVID-19 cases, hypercoagulability and inflammation are two crucial complications responsible for poor prognosis and mortality. In addition, coagulation system activation and inflammation overlap and produce life-threatening complications, including coagulopathy and cytokine storm, which are associated with overproduction of cytokines and activation of the immune system; they might be a lead cause of organ damage. ...
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research
ConclusionReports of fatal adverse reactions to coronavirus vaccines are very rare. Reports of CVST have been made in relation to both vaccines. Most were submitted after the reaction had been publicized. Thrombocytopenia occurred in a minority of cases. Reports linked both vaccines to cases of retinal vein thrombosis, just four  cases with thrombocytopenia. This suggests two different mechanisms of thrombosis associated with the vaccines.
Source: Drug Safety - Category: Drugs & Pharmacology Source Type: research
Conclusions: Compared with historical controls, VTE after adenovirus-based vaccination against SARS-CoV-2 is accompanied by thrombocytopenia, occurs in unusual sites, and is associated with worse clinical outcomes.
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
Malay Sarkar, Irappa V Madabhavi, Pham Nguyen Quy, Manjunath B GovindagoudarAnnals of Thoracic Medicine 2022 17(1):1-13 Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a highly transmissible and pathogenic coronavirus responsible for the pandemic coronavirus disease 19 (COVID-19). It has significant impact on human health and public safety along with negative social and economic consequences. Vaccination against SARS-CoV-2 is likely the most effective approach to sustainably control the global COVID-19 pandemic. Vaccination is highly effective in reducing the risk of severe COVID-19 disease. Mass-scale vac...
Source: Annals of Thoracic Medicine - Category: Respiratory Medicine Authors: Source Type: research
SUMMARY: Reports of a rare form of cerebral venous sinus thrombosis with profound thrombocytopenia have emerged following introduction of the adenovirus-vectored coronavirus disease 2019 (COVID-19) vaccines. Between March and June 2021, seven cases of refractory vaccine-induced immune thrombotic thrombocytopenia were referred to our institution for mechanical thrombectomy. The condition of 1 patient deteriorated during interhospital transfer, and the remaining 6 underwent successful recanalization. No procedure-related adverse events were reported. At the time of this writing, 3 patients have been discharged with a good fu...
Source: American Journal of Neuroradiology - Category: Radiology Authors: Tags: INTERVENTIONAL Source Type: research
Currently, the world is coping with the COVID-19 pandemic with a few vaccines. So far, the European Medicine Agency has approved four of them. However, following widespread vaccination with the recombinant adenoviral vector-based Oxford-AstraZeneca vaccine, available only in the United Kingdom and Europe, many concerns have emerged, especially the report of several cases of the otherwise rare cerebral sinus vein thrombosis and splanchnic vein thrombosis. The onset of thrombosis particularly at these unusual sites, about 5--14 days after vaccination, along with thrombocytopenia and other specific blood test abnormalities,...
Source: Journal of Cardiovascular Medicine - Category: Cardiology Tags: Reviews Source Type: research
A 68-years-old man presented to the emergency department for left leg swelling with subacute pain, associated with weakness, dizziness and progressive dyspnoea. His medical history included hypertension and an euthyroid nodular goiter; personal history of thrombosis were negative. Molecular test for SARS-Cov2 nucleic acid (PCR) was negative and anti-spike IgG levels were 316 AU/ml. Vaccination for Coronavirus disease 2019 (COVID-19) with a single dose of Janssen Ad26.COV2.S vaccine (Janssen vaccines, Leiden, The Netherlands) was reported 13 days before.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Tags: Case Report Source Type: research
Since the first cases were discovered at the end of 2019, the ongoing coronavirus disease 2019 (COVID-19) pandemic has significantly changed the lives of people around the world. Vaccines to prevent infection from its causative organism, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), were developed by the end of 2020 and have now become humanity's hope of regaining normalcy by acquiring protective immunity against COVID-19. However, as vaccines against COVID-19 have been distributed globally at an unprecedented rate, cases of serious adverse events post-vaccination have been accumulating.
Source: International Journal of Infectious Diseases - Category: Infectious Diseases Authors: Source Type: research
CONCLUSIONS: Vaccine-induced immune thrombotic thrombocytopenia is a serious complication of vaccination that is not feasible to anticipate or prevent. When the patient presents with sustained headache, neurologic symptoms/signs, abdominal pain, dyspnea, or limb pain/swelling beginning 5–30 days post vaccination, platelet count and d-dimer must be measured, and imaging for thrombosis performed. Confirmation of vaccine-induced immune thrombotic thrombocytopenia diagnosis should be ordered (platelet factor 4/polyanion enzyme-linked immunosorbent assay; platelet factor 4–enhanced platelet activation testing) a...
Source: Critical Care Medicine - Category: Emergency Medicine Tags: Online Review Article Source Type: research
NEW BRUNSWICK, N.J., December 16, 2021 – Johnson &Johnson remains confident in the overall positive benefit-risk profile of its COVID-19 vaccine. Studies have shown that the Johnson &Johnson COVID-19 vaccine generates strong antibody and cellular immune responses [i] and long-lasting immune memory[ii] and breadth of protection across variants. In addition, a growing body of evidence is revealing the strength of protection of our vaccine as a booster to either the Janssen COVID-19 vaccine or a different authorized or approved COVID-19 vaccine, both in terms of its efficacy and durability.[iii], [iv], [v], [vi]...
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
More News: Coronavirus | COVID-19 | Health Management | Hematology | Study | Thrombocytopenia | Thrombosis | Vaccines